Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review.
Bellman P, Gonzalez-Lugo JD, Shahzad M, Amin MK, Khalid MF, Suleman N, Ahmed N, Singh AK, Yacoub A, Zhang D, McGuirk JP, Mushtaq MU. Bellman P, et al. Among authors: mushtaq mu. Front Oncol. 2024 Apr 11;14:1383730. doi: 10.3389/fonc.2024.1383730. eCollection 2024. Front Oncol. 2024. PMID: 38665946 Free PMC article.
Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis.
Shahzad M, Hussain A, Tariq E, Anwar I, Faisal MS, Syed L, Karam A, Chaudhary SG, Ahmed N, Bansal R, Khurana S, Singh AK, Byrd KP, Hematti P, Abhyankar SH, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: mushtaq mu. Clin Lymphoma Myeloma Leuk. 2023 Mar;23(3):178-187. doi: 10.1016/j.clml.2023.01.002. Epub 2023 Jan 12. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36682989 Review.
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
Ahmed N, Wesson W, Mushtaq MU, Porter DL, Nasta SD, Brower J, Bachanova V, Hu M, Nastoupil LJ, Oluwole OO, Patel VG, Oliai C, Riedell PA, Bishop MR, Shah GL, Perales MA, Schachter L, Maziarz RT, McGuirk JP. Ahmed N, et al. Among authors: mushtaq mu. Transplant Cell Ther. 2023 Jul;29(7):449.e1-449.e7. doi: 10.1016/j.jtct.2023.04.019. Epub 2023 Apr 27. Transplant Cell Ther. 2023. PMID: 37120134 Free PMC article. Review.
Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.
Shahzad M, Nguyen A, Hussain A, Ammad-Ud-Din M, Faisal MS, Tariq E, Ali F, Butt A, Anwar I, Chaudhary SG, Lutfi F, Ahmed N, Singh AK, Hematti P, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: mushtaq mu. Front Immunol. 2023 Apr 24;14:1152457. doi: 10.3389/fimmu.2023.1152457. eCollection 2023. Front Immunol. 2023. PMID: 37168849 Free PMC article. Review.
Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy.
Lutfi F, Goloubeva O, Kowatli A, Gryaznov A, Kim DW, Dureja R, Margiotta P, Matsumoto LR, Bukhari A, Ahmed N, Mushtaq MU, Law JY, Lee ST, Kocoglu MH, Atanackovic D, Yared JA, Hardy NM, McGuirk JP, Rapoport AP, Chen W, Dahiya S. Lutfi F, et al. Among authors: mushtaq mu. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):757-763. doi: 10.1016/j.clml.2023.06.005. Epub 2023 Jun 19. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37453865 Free article.
"Waitlist mortality" is high for myeloma patients with limited access to BCMA therapy.
Ahmed N, Wesson W, Mushtaq MU, Bansal R, AbdelHakim H, Bromert S, Appenfeller A, Ghazal BA, Singh A, Abhyankar S, Ganguly S, McGuirk J, Abdallah AO, Shune L. Ahmed N, et al. Among authors: mushtaq mu. Front Oncol. 2023 Aug 3;13:1206715. doi: 10.3389/fonc.2023.1206715. eCollection 2023. Front Oncol. 2023. PMID: 37601685 Free PMC article.
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome: A systematic review and meta-analysis.
Shahzad M, Iqbal Q, Tariq E, Ammad-Ud-Din M, Butt A, Mushtaq AH, Ali F, Chaudhary SG, Anwar I, Gonzalez-Lugo JD, Abdelhakim H, Ahmed N, Hematti P, Singh AK, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: mushtaq ah, mushtaq mu. Crit Rev Oncol Hematol. 2024 Apr;196:104310. doi: 10.1016/j.critrevonc.2024.104310. Epub 2024 Feb 27. Crit Rev Oncol Hematol. 2024. PMID: 38423375 Free article. Review.
Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience.
McGuirk M, Shahzad M, Amin MK, Khan MA, Bellman P, Mudaranthakam DP, DeJarnette S, Lutfi F, Ahmed N, Bansal R, Abdelhakim H, Gorsline C, Shoemaker DM, Abdallah AO, Shune L, Abhyankar SH, Singh AK, McGuirk JP, Mushtaq MU. McGuirk M, et al. Among authors: mushtaq mu. Transpl Immunol. 2024 Jun;84:102039. doi: 10.1016/j.trim.2024.102039. Epub 2024 Mar 19. Transpl Immunol. 2024. PMID: 38513813 Free article.
62 results